🧠 DA Davidson downgrades $IONQ: 🔻 Buy → Neutral, target: $35 🗣️ Analyst: “The quantum revolution is coming, but IonQ’s short-term outlook is murky. The roadmap is unclear, and risks have increased.” 🚧 Investment continues, but visibility is low → A “stay on the sidelines” position has been adopted. ➡️ Long-term is exciting, short-term is a question mark... Not investment advice!!! #IONQ #QuantumComputing #Quantum #StockAnalysis #StockMarket

Oscar ($OSCR), like its competitors, has been negatively impacted by the rise in the US morbidity rate. Morbidity refers to the average health deterioration in the US population. While the exact cause is unknown, Americans are now less healthy. The impact is reflected in the "Medical loss ratio" line on the income statement. This means the company is now paying more premiums back to policyholders as claims. I thought morbidity could be a problem, but Oscar could manage it with artificial intelligence applications. It seems I was wrong, at least for now. I was predicting OSCR could better select and price patients with AI, but that's been a lie for now. 📈 Oscar Health 2025 Q2 Results Announced! 📉 Oscar Health announced its Q2 2025 financial results. While revenue and EPS fell short of expectations, the company maintained its year-end revenue guidance. Here are the details: 🔹 Revenue: 2.86 Billion (Expected 2.92 Billion) 🔴 🔹 Earnings per Share (EPS): -0.89 (Expected -0.84) 🔴 🔹 Memberships: 2.03 Million (+29% YoY increase) Annual revenue guidance remained unchanged at 12.0 Billion - 12.2 Billion. The company stated that it experienced a loss in the quarter due to increased risk adjustment costs in the insurance market. CEO Mark Bertolini: "We believe the individual market has long-term potential and that the future is in healthcare." #OscarHealth #OSCR #Finance #StockMarket #Technology #Healthcare #Investment #Economy

Novo Nordisk's Q2 earnings report fell short of expectations, but sales of its weight-loss drug Wegovy were impressive! 🟢 However, due to competition and slowing GLP-1 growth, the company lowered its full-year guidance and is considering a CEO change. 📉 #NovoNordisk #NVO #StockMarket #Finance #Wegovy #Ozempic #EarningsReport